HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.

AbstractBACKGROUND AND AIMS:
Cocaine use is prevalent among people receiving injectable opioid agonist treatment. Investigations of cocaine use in this population have been descriptive and the potential heterogeneity existing in patterns of use have not been characterized. As such, among patients receiving injectable opioid agonist treatment, this study aimed to: 1) quantify intra- and inter-individual variation in cocaine use over 24-months and; 2) determine how predictors of interest explained this variation.
METHODS:
Participants were patients receiving injectable opioid agonist treatment for opioid use disorder. Study visits were completed at baseline prior to receiving treatment, and 3,6,9,12,18, and 24 months after baseline. A multi-level regression approach to growth curve modeling was employed to estimate and explain intra- (within-person) and inter-individual (between-person) variation in cocaine use.
RESULTS:
Significant intra and inter-individual variation in cocaine use was identified over 24-months. Treatment engagement was on average associated with reductions in the prior month number of days of cocaine use (range: 0-30)(Estimate (standard error): -0.05(0.02), p = 0.003). On average, men reported less cocaine use compared to women (Estimate (standard error): -5.91(1.57), p=<0.001), and participants reporting ever regularly using cocaine at baseline reported more cocaine use over 24-months compared to participants reporting never regularly using cocaine (Estimate (standard error): 4.72 (1.91), p = 0.013).
CONCLUSIONS:
Significant reductions in cocaine use were observed and significant heterogeneity in patterns of cocaine use was identified. These heterogeneous cocaine use profiles suggest that an individualized approach to care will be critical in responding to patients' cocaine use in injectable opioid agonist treatment.
AuthorsHeather Palis, Daphne Guh, Scott MacDonald, Scott Harrison, Suzanne Brissette, David C Marsh, Martin T Schechter, Eugenia Oviedo-Joekes
JournalDrug and alcohol dependence (Drug Alcohol Depend) Vol. 218 Pg. 108333 (01 01 2021) ISSN: 1879-0046 [Electronic] Ireland
PMID33268225 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Elsevier B.V. All rights reserved.
Chemical References
  • Analgesics, Opioid
  • Heroin
  • Cocaine
  • Hydromorphone
Topics
  • Adult
  • Analgesics, Opioid (therapeutic use)
  • Cocaine (therapeutic use)
  • Cocaine-Related Disorders (epidemiology)
  • Female
  • Heroin (administration & dosage, therapeutic use)
  • Humans
  • Hydromorphone (administration & dosage, therapeutic use)
  • Male
  • Middle Aged
  • Opioid-Related Disorders (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: